CHD5 Is a Tumor Suppressor at Human 1p36

Cell

Volumn 128, Issue 3, 2007, Pages 459-475

  Bagchi, Anindya ^a   Papazoglu, Cristian ^a,b   Wu, Ying ^a   Capurso, Daniel ^a   Brodt, Michael ^a   Francis, Dailia ^a   Bredel, Markus ^c   Vogel, Hannes ^c   Mills, Alea A ^a  

^a Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P19; PROTEIN P19 ARF; PROTEIN P53; UNCLASSIFIED DRUG;

1P36 GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GENETICS; CARCINOGENESIS; CELL AGING; CELL PROLIFERATION; CHD5 GENE; CHROMOSOME LOSS; CONTROLLED STUDY; GENE DELETION; GENE INACTIVATION; GENE LOCATION; GENETIC ENGINEERING; HUMAN; NONHUMAN; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 33846703338     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cell.2006.11.052     Document Type: Article

References (53)

1. Bello M.J., Leone P.E., Vaquero J., de Campos J.M., Kusak M.E., Sarasa J.L., Pestana A., and Rey J.A. Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors. Int. J. Cancer 64 (1995) 207-210
2. Bieche I., Champeme M.-H., Matifas F., Cropp C.S., Callahan R., and Lidereau R. Two distinct regions involved in 1p deletion in human primary breast cancer. Cancer Res. 53 (1993) 1990-1994
3. Bredel M., Bredel C., Juric D., Harsh G.R., Vogel H., Recht L.D., and Sikic B.I. Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas. Cancer Res. 65 (2005) 8679-8689
4. Bredel M., Bredel C., Juric D., Harsh G.R., Vogel H., Recht L.D., and Sikic B.I. High-resolution genome-wide mapping of genetic alterations in human glial brain tumors. Cancer Res. 65 (2005) 4088-4096
5. Brodeur G.M., Sekhon G., and Goldstein M.N. Chromosomal aberrations in human neuroblastomas. Cancer 40 (1977) 2256-2263
6. Bruggeman S.W., Valk-Lingbeek M.E., van der Stoop P.P., Jacobs J.J., Kieboom K., Tanger E., Hulsman D., Leung C., Arsenijevic Y., Marino S., and van Lohuizen M. Ink4a and Arf differentially affect cell proliferation and neural stem cell self-renewal in Bmi1-deficient mice. Genes Dev. 19 (2005) 1438-1443
7. Call K.M., Glasser T., Ito C.Y., Buckler A.J., Pelletier J., Haber D.A., Rose E.A., Kral A., Yeger H., Lewis W.H., et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome II Wilm's tumour locus. Cell 60 (1990) 509-520
8. Cao R., Wang L., Wang H., Xia L., Erdjument-Bromage H., Tempst P., Jones R.S., and Zhang Y. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 298 (2002) 1039-1043
9. Cawthon R.M., Weiss R., Xu G., Viskochil D., Culver M., Stevens J., Robertson M., Dunn D., Gesteland R., O'Connell P., and White R. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell 62 (1990) 193-201
10. Chen W., Erdogan F., Ropers H.H., Lenzner S., and Ullmann R. CGHPRO-a comprehensive data analysis tool for array CGH. BMC Bioinformatics 6 (2005) 85
11. Cheung T.H., Lo K.W., Yim S.F., Poon C.S., Cheung A.Y., Chung T.K., and Wong Y.F. Clinicopathologic significance of loss of heterozygosity on chromosome 1 in cervical cancer. Gynecol. Oncol. 96 (2005) 510-515
12. Dickins R.A., Hemann M.T., Zilfou J.T., Simpson D.R., Ibarra I., Hannon G.J., and Lowe S.W. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat. Genet. 37 (2005) 1289-1295
13. Dimri G.P., Lee X., Basile G., Acosta M., Scott G., Roskelley C., Medrano E.E., Linskens M., Rubelj I., Pereira-Smith O., et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. USA 92 (1995) 9363-9367
14. Donehower L.A., Harvey M., Slagle B.L., McArthur M.J., Montgomery Jr. C.A., Butel J.S., and Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356 (1992) 215-221
15. Esteller M., Corn P.G., Baylin S.B., and Herman J.G. A gene hypermethylation profile of human cancer. Cancer Res. 61 (2001) 3225-3229
16. Fearon E.R., Cho K.R., Nigro J.M., Kern S.E., Simons J.W., Ruppert J.M., Hamilton S.R., Preisinger A.C., Thomas G., Kinzler K.W., and Vogelstein B. Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 247 (1990) 49-56
17. Flanagan J.F., Mi L.Z., Chruszcz M., Cymborowski M., Clines K.L., Kim Y., Minor W., Rastinejad F., and Khorasanizadeh S. Double chromodomains cooperate to recognize the methylated histone H3 tail. Nature 438 (2005) 1181-1185
18. Friend S.H., Horowitz J.M., Gerber M.R., Wang X.-F., Bogenmann E., Li F.P., and Weinberg R.A. Deletions of a DNA sequence in retinoblastomas and mesenchymal tumors: organization of the sequence and its encoded protein. Proc. Natl. Acad. Sci. USA 84 (1987) 9059-9063
19. Gessler M., Poustka A., Cavenee W., Neve R.L., Orkin S.H., and Bruns G.A.P. Homozygous deletion in Wilm's tumours of a zinc-finger gene identified by chromosome jumping. Nature 343 (1990) 774-778
20. Gonzalez S., and Serrano M. A new mechanism of inactivation of the INK4/ARF locus. Cell Cycle 5 (2006) 1382-1384
21. Hemann M.T., Fridman J.S., Zilfou J.T., Hernando E., Paddison P.J., Cordon-Cardo C., Hannon G.J., and Lowe S.W. An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nat. Genet. 33 (2003) 396-400
22. Hemann M.T., Zilfou J.T., Zhao Z., Burgess D.J., Hannon G.J., and Lowe S.W. Suppression of tumorigenesis by the p53 target PUMA. Proc. Natl. Acad. Sci. USA 101 (2004) 9333-9338
23. Jacobs J.J., Kieboom K., Marino S., DePinho R.A., and van Lohuizen M. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 397 (1999) 164-168
24. Jones D.O., Cowell I.G., and Singh P.B. Mammalian chromodomain proteins: their role in genome organisation and expression. Bioessays 22 (2000) 124-137
25. Juric D.B.C., Sikic B.I., and Bredel M. Integrated high-resolution genome-wide analysis of gene dosage and gene expression in human brain tumors. Methods Mol. Biol. 377 (2007) 187-202
26. Keyes W.M., Wu Y., Vogel H., Guo X., Lowe S.W., and Mills A.A. p63 deficiency activates a program of cellular senescence and leads to accelerated aging. Genes Dev. 19 (2005) 1986-1999
27. Kleer C.G., Bryant B.R., Giordano T.J., Sobel M., and Merino M.J. Genetic changes in chromosomes 1p and 17p in thyroid cancer progression. Endocr. Pathol. 11 (2000) 137-143
28. Knudsen A.G. Mutation and cancer: a statistical study of retinoblastoma. Proc. Natl. Acad. Sci. USA 68 (1971) 820-823
29. Law M.E., Templeton K.L., Kitange G., Smith J., Misra A., Feuerstein B.G., and Jenkins R.B. Molecular cytogenetic analysis of chromosomes 1 and 19 in glioma cell lines. Cancer Genet. Cytogenet. 160 (2005) 1-14
30. Lee W.-H., Bookstein R., Hong F., Young L.-J., Shew J.-Y., and Lee E.Y.-H.P. Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science 235 (1987) 1394-1399
31. Lowe S.W., and Sherr C.J. Tumor suppression by Ink4a-Arf: progress and puzzles. Curr. Opin. Genet. Dev. 13 (2003) 77-83
32. Melendez B., Cuadros M., Robledo M., Rivas C., Fernandez-Piqueras J., Martinez-Delgado B., and Benitez J. Coincidental LOH regions in mouse and humans: evidence for novel tumor suppressor loci at 9q22-q34 in non-Hodgkin's lymphomas. Leuk. Res. 27 (2003) 627-633
33. Miki Y., Swensen J., Shattuck-Eidens D., Futreal P.A., Harshman K., Tavtigian S., Liu Q., Cochran C., Bennett L.M., Ding W., et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266 (1994) 66-71
34. Mills A.A., and Bradley A. From mouse to man: generating megabase chromosome rearrangements. Trends Genet. 17 (2001) 331-339
35. Moley J.F., Brother M.B., Fong C.T., White P.S., Baylin S.B., Nelkin B., Wells S.A., and Brodeur G.M. Consistent association of 1p loss of heterozygosity with pheochromocytomas from patients with multiple endocrine neoplasia type 2 syndromes. Cancer Res. 52 (1992) 770-774
36. Mori N., Morosetti R., Spira S., Lee S., Ben-Yehuda D., Schiller G., Landolfi R., Mizoguchi H., and Koeffler H.P. Chromosome band 1p36 contains a putative tumor suppressor gene important in the evolution of chronic myelocytic leukemia. Blood 92 (1998) 3405-3409
37. Mori N., Morosetti R., Mizoguchi H., and Koeffler H.P. Progression of myelodysplastic syndrome: allelic loss on chromosomal arm 1p. Br. J. Haematol. 122 (2003) 226-230
38. Muller J., Hart C.M., Francis N.J., Vargas M.L., Sengupta A., Wild B., Miller E.L., O'Connor M.B., Kingston R.E., and Simon J.A. Histone methyltransferase activity of a Drosophila Polycomb group repressor complex. Cell 111 (2002) 197-208
39. Olshen A.B., Venkatraman E.S., Lucito R., and Wigler M. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 5 (2004) 557-572
40. Piaskowski S., Rieske P., Szybka M., Wozniak K., Bednarek A., Pluciennik E., Jaskolski D., Sikorska B., and Liberski P.P. GADD45A and EPB41 as tumor suppressor genes in meningioma pathogenesis. Cancer Genet. Cytogenet. 162 (2005) 63-67
41. Poetsch M., Dittberner T., and Woenckhaus C. Microsatellite analysis at 1p36.3 in malignant melanoma of the skin: fine mapping in search of a possible tumour suppressor gene region. Melanoma Res. 13 (2003) 29-33
42. Praml C., Finke L.H., Herfarth C., Schlag P., Schwab M., and Amler L. Deletion mapping defines different regions in 1p34.2-pter that may harbor genetic information related to human colorectal cancer. Oncogene 11 (1995) 1357-1362
43. Pray-Grant M.G., Daniel J.A., Schieltz D., Yates III J.R., and Grant P.A. Chd1 chromodomain links histone H3 methylation with SAGA- and SLIK-dependent acetylation. Nature 433 (2005) 434-438
44. Ramirez-Solis R., Liu P., and Bradley A. Chromosome engineering in mice. Nature 378 (1995) 720-724
45. Serrano M., Lin A.W., McCurrach M.E., Beach D., and Lowe S.W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88 (1997) 593-602
46. Storey J.D., and Tibshirani R. Statistical significance for genomewide studies. Proc. Natl. Acad. Sci. USA 100 (2003) 9440-9445
47. Thompson P.M., Gotoh T., Kok M., White P.S., and Brodeur G.M. CHD5, a new member of the chromodomain gene family, is preferentially expressed in the nervous system. Oncogene 22 (2003) 1002-1011
48. Valk-Lingbeek M.E., Bruggeman S.W., and van Lohuizen M. Stem cells and cancer; the polycomb connection. Cell 118 (2004) 409-418
49. Wallace M.R., Marchuk D.A., Anderson L.B., Letcher R., Odeh H.M., Saulino A.M., Fountain J.W., Brereton A., Nicholson J., Mitchell A.L., et al. Type I neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 249 (1990) 181-189
50. White P.S., Maris J.M., Beltinger C., Sulman E., Marshall H.N., Fujimori M., Kaufman B.A., Biegel J.A., Allen C., Hilliard C., et al. A region of consistent deletion in neuroblastoma maps within human chromosome 1p36.2-36.3. Proc. Natl. Acad. Sci. USA 92 (1995) 5520-5524
51. White P.S., Thompson P.M., Gotoh T., Okawa E.R., Igarashi J., Kok M., Winter C., Gregory S.G., Hogarty M.D., Maris J.M., and Brodeur G.M. Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma. Oncogene 24 (2005) 2684-2694
52. Wooster R., Bignell G., Lancaster J., Swift S., Seal S., Mangion J., Collins N., Gregory S., Gumbs C., Micklem G., et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 378 (1995) 789-792
53. Wysocka J., Swigut T., Xiao H., Milne T.A., Kwon S.Y., Landry J., Kauer M., Tackett A.J., Chait B.T., Badenhorst P., et al. A PHD finger of NURF couples histone H3 lysine 4 trimethylation with chromatin remodelling. Nature 442 (2006) 86-90